

SELECTED PUBLICATIONS

Jeffrey A Cohen, MD

Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Rudick RA, Sandrok AW, Simon JH, Simonian NA, Tsao EC, Whitaker JN, for the IMPACT Investigators. Benefit of intramuscular interferon beta-1a on MSFC progression in secondary progressive MS. *Neurology* 2002;59:679-687.

Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. *Neurology* 2007;68:939-944.

Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M for the ACT Investigators. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. *Neurology* 2009;72:535-541.

Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH. Differential diagnosis of suspected multiple sclerosis: a consensus approach. *Mult Scler* 2008;14:1157-1174.

Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, for the TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon in relapsing multiple sclerosis. *N Engl J Med* 2010;362:402-415.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the "McDonald Criteria." *Ann Neurol* 2011;69:292-302.

Cohen JA, Reingold SC, Polman CH, Wolinsky JS, on behalf of the International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcomes in multiple sclerosis clinical trials: current status and future prospects. *Lancet Neurol* 2012;11:467-476.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara M, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet* 2012;380:1819-1828.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Soelberg Sorensen P, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetski C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani, MP, Stuve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology* 2014;83:278-286.

Cohen JA, Krishnan AV, Goodman AD, Potts J, Wang P, Havrdova E, Polman C, Rudick RA. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis. *JAMA Neurol* 2014;71:1386-1393.

Balcer LJ, Miller DH, Reingold SC, Cohen JA. Vision and vision-related outcome measures in multiple sclerosis. *Brain* 2015;138:11-27.

Cohen JA, Belova A, Selmaj K, Wolf C, Oberyé J, van den Tweel E, PhD, Mulder R, Koper N, Voortman G, Barkhof F, for the GATE Study Group. Equivalence of generic glatiramer acetate in multiple sclerosis. *JAMA Neurol* 2015;72:1433-1441.

Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, Cravets M, Olson A, Frohna PA, and Selmaj KW, for the RADIANCE Study Group. Efficacy and safety of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis. *Lancet Neurol* 2016;15:373-381.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. *Mult Scler J* published online 06 April 2017 DOI: 10.1177/1352458517703802.

Scolding NJ, Pasquini M, Reingold SC, Cohen JA. Cell-based therapeutic strategies for multiple sclerosis. *Brain* (in press).

Sargent A, Bai L, Shano G, Karl M, Garrison E, Ranasinghe L, Planchon S, Cohen J, Miller R. CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. *Exp Neurol* (in press).

Invited Reviews

Conway D, Cohen JA. Combination therapy in multiple sclerosis. *Lancet Neurol* 2010;9:299-308.

Bermel RA, Cohen JA. 2010 Roundup. Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options. *Lancet Neurol* 2011;10:4-5.

Cohen JA, Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. *Ann Neurol* 2011;69:759-777.

Ontaneda D, Hyland M, Cohen, JA. Multiple sclerosis: news insights in pathogenesis and novel therapeutics. *Ann Rev Med* 2012;63:389-404.

Ontaneda D, Thompson AJ, Fox RJ, Cohen JA. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. *Lancet* 2017;389(10076):1357-1366.

Books

Cohen JA and Rudick RA (eds). *Multiple Sclerosis Therapeutics, 4th Edition*. Cambridge University Press, Cambridge, 2011.

Cohen JA and Rae-Grant A. *Handbook of Multiple Sclerosis*. Springer Healthcare, London, 2012.